LU91393I2 - "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix - Google Patents

"La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix

Info

Publication number
LU91393I2
LU91393I2 LU91393C LU91393C LU91393I2 LU 91393 I2 LU91393 I2 LU 91393I2 LU 91393 C LU91393 C LU 91393C LU 91393 C LU91393 C LU 91393C LU 91393 I2 LU91393 I2 LU 91393I2
Authority
LU
Luxembourg
Prior art keywords
protein
cervarix
combination
recombinant human
human papillomavirus
Prior art date
Application number
LU91393C
Other languages
English (en)
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25416951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91393(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of LU91393I2 publication Critical patent/LU91393I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU91393C 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix LU91393I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90310992A 1992-06-25 1992-06-25
PCT/US1993/006109 WO1994000152A1 (fr) 1992-06-25 1993-06-24 Vaccin contre le papillomavirus

Publications (1)

Publication Number Publication Date
LU91393I2 true LU91393I2 (fr) 2008-02-14

Family

ID=25416951

Family Applications (8)

Application Number Title Priority Date Filing Date
LU91395C LU91395I2 (fr) 1992-06-25 2005-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18"-Cervarix
LU91398C LU91398I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard
LU91399C LU91399I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16" Gardasil-Silgard
LU91397C LU91397I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard
LU91394C LU91394I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix
LU91393C LU91393I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix
LU91396C LU91396I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard
LU91400C LU91400I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18" Gardasil-Silgard

Family Applications Before (5)

Application Number Title Priority Date Filing Date
LU91395C LU91395I2 (fr) 1992-06-25 2005-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18"-Cervarix
LU91398C LU91398I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard
LU91399C LU91399I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16" Gardasil-Silgard
LU91397C LU91397I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard
LU91394C LU91394I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix

Family Applications After (2)

Application Number Title Priority Date Filing Date
LU91396C LU91396I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard
LU91400C LU91400I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18" Gardasil-Silgard

Country Status (12)

Country Link
US (2) US20020068326A1 (fr)
EP (2) EP0647140B1 (fr)
AT (1) ATE380871T1 (fr)
AU (1) AU697743C (fr)
DE (9) DE122007000099I1 (fr)
DK (1) DK0647140T3 (fr)
ES (1) ES2294778T3 (fr)
FR (1) FR07C0073I2 (fr)
LU (8) LU91395I2 (fr)
NL (8) NL300319I1 (fr)
PT (1) PT647140E (fr)
WO (1) WO1994000152A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000018I1 (de) 1991-07-19 2007-05-24 Univ Queensland Polynukleotidabschnitt des HPV16-Genoms
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
PL183781B1 (pl) * 1994-05-16 2002-07-31 Merck & Co Inc Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków
AU683564B2 (en) * 1994-05-17 1997-11-13 University Of Queensland, The Recombinant papilloma virus L1
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
EP0782615A4 (fr) * 1994-09-22 2001-08-22 Merck & Co Inc Adn codant pour le papillomavirus humain du type 6a
US6066324A (en) 1994-10-07 2000-05-23 Loyola University Of Chicago Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP1000157A1 (fr) * 1997-07-03 2000-05-17 University Technology Corporation Compositions renfermant des capsomeres de papillomavirus humain homogene, leurs procedes de production et leurs procedes d'utilisation en tant qu'agents diagnostiques, prophylactiques ou therapeutiques
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO2000002924A1 (fr) * 1998-07-13 2000-01-20 Loyola University Of Chicago Recepteur cellulaire du papillomavirus
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
AU750587B2 (en) * 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
ATE471990T1 (de) 2001-08-13 2010-07-15 Univ Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
SI2137210T1 (sl) 2007-03-02 2017-01-31 Glaxosmithkline Biologicals S.A. Nov postopek in sestavki
CN106377767A (zh) 2008-05-26 2017-02-08 卡迪拉保健有限公司 麻疹‑人乳头瘤组合疫苗
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
ES2643498T3 (es) 2010-04-08 2017-11-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ensayo de células presentadoras de antígenos de linfocitos B
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
EP2912069B1 (fr) 2012-10-23 2019-07-31 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
WO2017200852A1 (fr) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation contenant un agoniste de tlr et procédés d'utilisation
MX2021010105A (es) 2016-06-01 2022-06-16 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
CA3067224A1 (fr) 2017-06-15 2018-12-20 Infectious Disease Research Institute Supports lipidiques nanostructures et emulsions stables et leurs utilisations
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
CA3141577A1 (fr) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition et procede de sechage par atomisation d'une emulsion de vaccin et d'adjuvant
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2024052882A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4455296A (en) * 1982-02-02 1984-06-19 Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2524487B1 (fr) * 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US4596674A (en) * 1984-09-11 1986-06-24 Merck & Co., Inc. Immunogenic HAV peptides
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
EP0320942A3 (fr) * 1987-12-18 1989-10-04 American Cyanamid Company Polysaccharides et composés macromoléculaires contenant ces polysaccharides
IE910909A1 (en) * 1990-03-20 1991-09-25 Behringwerke Ag Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins
DE122007000018I1 (de) 1991-07-19 2007-05-24 Univ Queensland Polynukleotidabschnitt des HPV16-Genoms

Also Published As

Publication number Publication date
DE122007000100I1 (de) 2008-03-27
NL300319I1 (nl) 2008-03-03
ES2294778T3 (es) 2008-04-01
LU91399I2 (fr) 2008-02-14
NL300315I2 (nl) 2008-03-03
DE122007000097I1 (de) 2008-03-27
DE122007000101I1 (de) 2008-03-27
NL300320I1 (nl) 2008-03-03
NL300315I1 (nl) 2008-02-01
LU91397I2 (fr) 2008-02-14
NL300318I1 (nl) 2008-02-01
LU91395I2 (fr) 2008-02-14
AU697743B2 (en) 1998-10-15
EP0647140B1 (fr) 2007-12-12
DE122007000094I1 (de) 2008-03-27
LU91394I2 (fr) 2008-02-14
DE122007000099I1 (de) 2008-03-27
US8012679B1 (en) 2011-09-06
LU91400I2 (fr) 2008-02-14
DE122007000096I1 (de) 2008-03-27
AU697743C (en) 2007-06-14
EP0647140A4 (fr) 1997-03-19
DE69334192T2 (de) 2008-12-04
ATE380871T1 (de) 2007-12-15
AU1135295A (en) 1996-02-08
EP0647140A1 (fr) 1995-04-12
NL300316I1 (nl) 2008-02-01
LU91396I2 (fr) 2008-02-14
NL300317I1 (nl) 2008-02-01
PT647140E (pt) 2007-12-27
NL300318I2 (nl) 2008-03-03
DE122007000095I1 (de) 2008-03-27
DK0647140T3 (da) 2008-02-04
US20020068326A1 (en) 2002-06-06
WO1994000152A1 (fr) 1994-01-06
DE122007000098I1 (de) 2008-03-27
FR07C0073I2 (fr) 2012-08-03
FR07C0073I1 (fr) 2008-01-02
DE69334192D1 (de) 2008-01-24
NL300322I1 (nl) 2008-03-03
NL300321I1 (nl) 2008-03-03
EP1835029A1 (fr) 2007-09-19
LU91398I2 (fr) 2008-02-14

Similar Documents

Publication Publication Date Title
LU91393I2 (fr) "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix
DE122008000010I1 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus-hüllproteine